The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center)
Cited by 739
Related Papers
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
|Proceedings of the National Academy of Sciences|2019|357
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
|The Journal of Experimental Medicine|2010|271
Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses
|The Journal of Immunology|2011|203
Attenuated T Cell Responses to a High-Potency Ligand In Vivo
|PLoS Biology|2010|112
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
|Nature Communications|2021|60